Modernization of Tissue-based, Biomarker-led Clinical Research

Dr Stephanie G. Craig, Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast

RELATED PRODUCTS
RELATED TAGS AND TOPICS
Automated Digital Workflow, Whole Slide Imaging, Digital Analysis, Multiplex
SHARE

Contact you research expert

Automated staining platforms and digital slide scanners have revolutionized tissue-based biomarker research by providing a powerful platform in which to conduct reproducible, quantitative biomarker-led studies at scale.

Use of machine learning and artificial intelligence approaches to analyze these biomarkers enables sensitive, specific, and rapid biomarker assessment in situ. In this talk, we will be reviewing the implementation and technical challenges faced in modern tissue-based, biomarker-led research from wet-lab validation to digital assessment. To do so we will review published work from our lab that has utilized automated staining and slide digitization as an aid to clinical research (for research use only. Not for use in diagnostic procedures) in immunohistochemistry, RNA in situ hybridization, multiplex immunofluorescence, and artificial intelligence studies.

If you have viewed this educational webinar or training and would like to apply for continuing education credits with your certifying organization, please download the form to assist you in adding self-reported educational credits to your transcript.
Apply for self-reported educational credits

Learning Objectives

  • Learn how automated staining and slide digitization can reduce staining variability and aid in quantitative biomarker assessment at scale
  • Understand how digitization of molecular pathology assessment lends itself to multi- and cross-disciplinary research investigations

For Research Use Only. Not for use in diagnostic procedures.

El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.

Copyright © 2022 Leica Biosystems division of Leica Microsystems, Inc. y sus filiales de Leica Biosystems. Todos los derechos reservados. LEICA y el logotipo de Leica son marcas comerciales registradas de Leica Microsystems IR GmbH.

About the presenter

Dr Stephanie G. Craig, Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen's University Belfast

Stephanie is a Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen’s University Belfast. She has a breath of experience in the application and validation of translational cancer research methodologies using molecular pathology techniques (immunohistochemistry, in situ hybridisation, multiplex immunofluorescence) and statistics. Her research focuses on predictive biomarker studies and understanding confounding variables that influence the prediction of poor prognosis subgroups in cancer research including reproducible study design, choice of molecular test and assessment criteria.